A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer: Lissoni P, Meregalli S, Fossati V, Paolorossi F, Barni S, Tancini G. et al. Divisione di Radioterapia, Ospedale San Gerardo, 20052 Monza. Tumori 1994; 80:464–467

doi:10.1016/0169-5002(95)90699-1

A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer: Lissoni P, Meregalli S, Fossati V, Paolorossi F, Barni S, Tancini G. et al. Divisione di Radioterapia, Ospedale San Gerardo, 20052 Monza. Tumori 1994; 80:464–467

https://doi.org/10.1016/0169-5002(95)90699-1

Copy DOI

Journal: Lung Cancer

Publication Date: Oct 1, 1995

#Low-dose Subcutaneous Interleukin-2 #Advanced Non-small Cell Lung Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer: Lissoni P, Meregalli S, Fossati V, Paolorossi F, Barni S, Tancini G. et al. Divisione di Radioterapia, Ospedale San Gerardo, 20052 Monza. Tumori 1994; 80:464–467

Full Text